<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers

20121,547 citationsJournal Articlebronze Open Access

Authors

Kristin Bergethon · Apple (Israel)

Alice T. Shaw · Apple (Israel)

Sai‐Hong Ignatius Ou · Apple (Israel)

Ryohei Katayama · Apple (Israel)

Christine M. Lovly · Apple (Israel)

Nerina T. McDonald · Apple (Israel)

Pierre P. Massion ·

Abstract

ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLC. Crizotinib shows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies RNA modifications and cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 8, pp. 863-870

DOI: 10.1200/jco.2011.35.6345

Field-Weighted Citation Impact: 130.38